<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1920_S09_C05_p067_092_8P</title>
		<link href="BCSC1920_S09_C05_p067_092_8P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1920_S09_C05_p067_092_8P" lang="en-US">
		<div id="_idContainer005" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter</span><span class="cn-chap"> </span>5</p>
			<p class="chapter-title ParaOverride-1">Diagnostic Considerations in Uveitis</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer000" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="video-list-mid ParaOverride-2"><span class="CharOverride-1">&#9;</span><span class="video-list-mid_italic CharOverride-1">This chapter includes a related video, which can be accessed by scanning the QR code provided in the text or &#173;going to </span><a href="http://www.aao.org/bcscvideo_section09"><span class="video-list-mid_italic CharOverride-1">www.&#173;aao.&#173;org/&#173;bcscvideo_&#173;section09</span></a><span class="video-list-mid_italic CharOverride-1">.</span></p>
			<p class="video-list-mid ParaOverride-3"><span class="CharOverride-1">&#9;</span><span class="video-list-mid_italic CharOverride-1">This chapter includes a related activity, which can be accessed by scanning the QR code provided in the text or &#173;going to </span><a href="http://www.aao.org/bcscactivity_section09"><span class="video-list-mid_italic CharOverride-1">www.&#173;aao.&#173;org/&#173;bcscactivity_&#173;section09</span></a><span class="video-list-mid_italic CharOverride-1">.</span></p>
			<p class="h1">Highlights</p>
			<div id="Chapt5_Top1">
			<p class="body-text--no-indent-">
			<ul>
				<li class="bullet-list-mid"><span class="bullet-list-first_italic">Uveitis</span> refers to a heterogeneous group of diseases characterized by intraocular inflammation, and accounts for significant visual morbidity worldwide.</li>
				<li class="bullet-list-mid">Diseases with similar clinical features can have dif&#173;fer&#173;ent prognoses and treatments, making accurate diagnosis imperative.</li>
				<li class="bullet-list-mid">A formalized nomenclature is used to describe, categorize, and grade uveitis by clinical and anatomical features.</li>
				<li class="bullet-list-mid">The patient history, review of systems, and targeted systemic examination combined with this naming scheme generate the differential diagnosis.</li>
				<li class="bullet-list-mid">Laboratory workup and ancillary testing are tailored to the patient and disease characteristics.</li>
			</ul>
			</p>
			</div>
			<p class="h1 ParaOverride-4">Overview</p>
			<div id="Chapt5_Top2">
			<p class="body-text--no-indent-">The uvea consists of the &#173;middle, pigmented, vascular layer of the eye and includes the iris, ciliary body, and choroid. <span class="italic">Uveitis</span> is broadly defined as inflammation (ie, <span class="italic">-&#173;itis</span>) of the uvea (from the Latin <span class="italic">uva,</span> meaning “grape”). Inflammation of the uvea can involve other ocular structures such as the ret&#173;ina, sclera, cornea, vitreous, and optic nerve. The etiology of uveitis is infectious or inflammatory and is variably associated with systemic disease.</p>
			<p class="body-text">&#173;Because uveitis can be associated with systemic disease or infection, a careful history and review of systems is an essential first step in diagnosis. A comprehensive physical examination of the eye and pertinent organ systems is performed to characterize the type of inflammation pres&#173;ent and to identify any associated systemic findings. The anatomical location of inflammation combined with results from the history and physical examination helps to guide further investigations. Multimodal ophthalmic imaging has an impor&#173;tant role in characterizing certain types of intraocular inflammation. Laboratory studies can help determine the etiology of the intraocular inflammation but are never a substitute for a thorough history and physical examination. Determining the specific type of uveitis guides the se&#173;lection of treatment (see <span class="body-text_xref-local">Chapter&#160;6</span>).</p>
			</div>
			<p class="h1 ParaOverride-5">Epidemiology</p>
			<div id="Chapt5_Top3">
			<p class="body-text--no-indent-">Uveitis is responsible for approximately 10% of all blindness in the United States and Eu&#173;rope and up to 25% of blindness worldwide. In the United States, the prevalence of uveitis is 58–131 per 100,00 and is up to 1070 per 100,000&#160;in the developing world. Anterior uveitis is the most common type of uveitis, representing 70%–80% of cases, followed by panuveitis, posterior uveitis, and intermediate uveitis. &#173;Women have slightly higher rates of uveitis overall. Although most surveys show that uveitis incidence peaks between 20 and 60&#160;years of age, recent data suggests that it may also increase over the age of 65. Prevalence is about five-&#173; to tenfold lower in &#173;children than in adults. Developing countries have higher rates of infectious uveitis and posterior and panuveitis compared to industrialized nations. Certain uveitides have greater distribution by geographic region, such as birdshot chorioretinopathy in western Eu&#173;rope, Beh<span class="body-text--no-indent-_accent">ç</span>et disease in Turkey and China, and tuberculous uveitis in India. <span class="body-text--no-indent-_xref-local">Chapters&#160;8 and 9</span> discuss specific uveitic entities in further detail.</p>
			<p class="reference--journal--first">Acharya NR, Tham VM, Esterberg E, et&#160;al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. <span class="reference--journal-_italic">JAMA Ophthalmol.</span> 2013;131(11):1405–1412.</p>
			<p class="reference--journal--mid">Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. <span class="reference--journal-_italic">Ophthalmology.</span> 2004;111(3):491–500.</p>
			<p class="reference--journal--mid">Rathinam SR, Krishnadas R, Ramakrishnan R, Thulasiraj RD, Tielsch JM, Katz J, Robin AL, Kempen JH; Aravind Comprehensive Eye Survey Research Group. Population-&#173;based prevalence of uveitis in Southern India. <span class="reference--journal-_italic">Br J Ophthalmol.</span> 2011;95:463–467.</p>
			<p class="reference--journal--mid">Rim TH, Kim SS, Ham D, Yu S, Chung EJ, Lee SC; Korean Uveitis Society. Incidence and prevalence of uveitis in South &#173;Korea: a nationwide cohort study. <span class="reference--journal-_italic">Br J Ophthalmol</span>. 2018; 102(1):79–83.</p>
			<p class="reference--journal--mid">Thorne JE, Suhler E, Skup M, Tari S, et&#160;al. Prevalence of noninfectious uveitis in the United States: a claims-&#173;based analy&#173;sis. <span class="reference--journal-_italic">JAMA Ophthalmol</span>. 2016;134(11):123–1245.</p>
			</div>
			<p class="h1 ParaOverride-5">Classification of Uveitis</p>
			<div id="Chapt5_Top4">
			<p class="body-text--no-indent-">In 2005, the world’s major uveitis socie&#173;ties instituted a standard of nomenclature pro&#173;cess, termed the Standardization of Uveitis Nomenclature (SUN) system. Uveitis specialists have widely accepted the SUN system of classification as a universal method of describing uveitis entities based on anatomic location of inflammation and specific descriptors of onset, duration, and course.</p>
			<p class="body-text">This text uses an etiologic division of uveitic entities into noninfectious (autoimmune) and infectious conditions and further describes them using the SUN system’s basic anatomical classification of uveitis into 4 subcategories: (1) anterior uveitis, (2) interme&#173;diate uveitis, (3) posterior uveitis, and (4) panuveitis. When both anterior chamber and vitreous inflammatory cells are pres&#173;ent, but the vitritis is more than expected in an isolated anterior uveitis, the classification should be “anterior and intermediate uveitis” and not “panuveitis.”</p>
			<p class="body-text"><span class="body-text_xref-table">&#173;Table&#160;5-1</span> reviews &#173;these 4 groups. The SUN system further refines this anatomical classification of uveitis by defining descriptors based on clinical onset, duration, and course (<span class="body-text_xref-table">&#173;Table&#160;5-2</span>). In addition, specific terminology for grading and monitoring uveitic activity is described in <span class="body-text_xref-table">&#173;Table&#160;5-3</span>.</p>
			<p class="reference--journal--single ParaOverride-6">Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. <span class="reference--journal-_italic">Am J Ophthalmol.</span> 2005;140(3):509–516.</p>
			<p class="h2">Anatomical Classification</p>
			<p class="h3-h2">Anterior uveitis</p>
			<p class="body-text--no-indent-">Anterior uveitis produces inflammatory signs predominantly in the anterior chamber, as a result of inflammation of the iris and ciliary body. Inflammation confined to the anterior chamber can be called <span class="italic">iritis</span>; if &#173;there are cells in the retrolental (anterior vitreous) space, it can be called <span class="italic">iridocyclitis</span>. Inflammatory pro&#173;cesses that originate in the cornea with secondary involvement of the anterior chamber are called <span class="italic">keratouveitis.</span> An inflammatory reaction that involves the sclera and uveal tract is called <span class="italic">sclerouveitis</span>.</p>
			<p class="body-text">When more than one ocular structure is involved, the convention is that the primary site of inflammation is named first. Severe or chronic anterior uveitis may produce secondary structural complications such as uveitic macular edema, optic disc swelling, cataract, corneal edema, band keratopathy, or iris abnormalities. &#173;These complications are not part of the formal classification system but may contribute to disease recognition and therapy. <span class="body-text_xref-table">&#173;Table&#160;5-4</span> includes a simplified scheme for patient evaluation in uveitis. (<span class="body-text_xref-local">Chapter&#160;8</span> discusses anterior uveitis in greater detail.)</p>
			<p class="h3">Intermediate uveitis</p>
			<p class="body-text--no-indent-">In intermediate uveitis, inflammation is most prominent in the vitreous cavity. Inflammation occurs in the ciliary body, pars plana and/or peripheral ret&#173;ina. Clinical signs include vitreous haze and cellular debris that is often associated with peripheral ret&#173;i&#173;nal vasculitis. Macular edema is the most common structural complication; severe or chronic disease may cause peripheral exudative or tractional detachments, ret&#173;i&#173;nal neovascularization, cataract, or retrolental membrane formation. The diagnostic term, <span class="italic">pars planitis</span>, refers to the subset of intermediate uveitis in which &#173;there are peripheral preret&#173;i&#173;nal collections of exudative and inflammatory debris in the absence of an associated infection or systemic disease (see <span class="body-text--no-indent-_xref-table">&#173;Table&#160;5-4</span>). (<span class="body-text--no-indent-_xref-local">Chapter&#160;8</span> discusses intermediate uveitis in greater detail.)</p>
			<p class="h3">Posterior uveitis</p>
			<p class="body-text--no-indent-">Posterior uveitis is defined as intraocular inflammation primarily involving the ret&#173;ina and/or choroid. Inflammatory cells may be observed diffusely throughout the vitreous cavity, overlying foci of active inflammation, or on the posterior vitreous face. Fundoscopy reveals focal, multifocal, or diffuse areas of retinitis and/or choroiditis, or ret&#173;i&#173;nal vasculitis. Entities may have a similar clinical appearance, though some clinical patterns of disease are nearly pathog&#9;nomonic for diagnosis. Structural complications such as macular edema, peripheral ret&#173;i&#173;nal vasculitis, epiret&#173;i&#173;nal membrane, and ret&#173;i&#173;nal or choroidal neovascularization are not sufficient for the anatomical classification of posterior uveitis (see <span class="body-text--no-indent-_xref-table">&#173;Table&#160;5-4</span>). (<span class="body-text--no-indent-_xref-local">Chapters 9–11</span> discuss noninfectious and infectious posterior uveitis in greater detail.)</p>
			<p class="h3 ParaOverride-7">Panuveitis</p>
			<p class="body-text--no-indent-">In panuveitis, inflammation is pres&#173;ent diffusely throughout the eye without a predominantly affected site. Inflammation may be associated with an infectious or noninfectious systemic disease (see <span class="body-text--no-indent-_xref-table">&#173;Table&#160;5-4</span>). (<span class="body-text--no-indent-_xref-local">Chapters&#160;9–11</span> discuss noninfectious and infectious panuveitis in greater depth, and <span class="body-text--no-indent-_xref-local">Chapter&#160;12</span> covers endophthalmitis.)</p>
			<p class="h3 ParaOverride-7">Ret&#173;i&#173;nal vasculitis</p>
			<p class="body-text--no-indent-">Ret&#173;i&#173;nal vasculitis is defined by the presence of ret&#173;i&#173;nal vascular changes in association with ocular inflammation. The term <span class="italic">ret&#173;i&#173;nal vasculitis</span> is used in distinction to <span class="italic">vasculopathy</span>, in which &#173;there are vessel changes but no vis&#173;i&#173;ble evidence of inflammation. <span class="italic">Ret&#173;i&#173;nal vasculitis</span> encompasses perivascular sheathing, vascular leakage, or occlusion shown on fluorescein angiography studies. Peripheral vascular sheathing can be observed in intermediate uveitis but is not sufficient for the anatomical classification of posterior/panuveitis<span class="body-text--no-indent-_bold">.</span> Ret&#173;i&#173;nal vasculitis is not considered to be a defining feature for the anatomical classification of uveitis. Table 5-5 summarizes diseases associated with retinal vasculitis.</p>
			<p class="h2 ParaOverride-8">Classification by Clinical Features</p>
			<p class="body-text--no-indent-">When uveitis symptoms begin quickly, the onset is termed <span class="italic">sudden</span>; when gradual, the onset is termed <span class="italic">insidious</span>. The clinical course of uveitis may be acute, chronic, or recurrent. <span class="italic">Acute uveitis</span> describes episodes of sudden onset and limited duration that usually resolve within 3 months or less. <span class="italic">Chronic uveitis</span> is per&#173;sis&#173;tent, with relapse occurring in less than 3 months &#173;after discontinuing treatment. <span class="italic">Recurrent uveitis</span> involves repeated episodes separated by periods of inactivity without treatment that last 3 months or longer.</p>
			<p class="body-text">The severity of the inflammation can influence categorization and prognosis. The inflammatory pro&#173;cess may occur in one or both eyes, or it may alternate between them. The distribution of ocular involvement—&#173;focal, multifocal, or diffuse—is also helpful to note when classifying uveitis.</p>
			<p class="body-text">The classification of uveitis as &#173;either granulomatous or nongranulomatous is still in use. However, that the <span class="italic">clinical</span> appearance of uveitis as granulomatous or nongranulomatous may not necessarily correlate with the <span class="italic">histologic</span> description and can instead be related to the disease stage, the amount of antigen at pre&#173;sen&#173;ta&#173;tion, or the patient’s state of immunocompromise (eg, a patient being treated with corticosteroids). <span class="italic">Nongranulomatous</span> inflammation typically has a lymphocytic and plasma cell infiltrate; clinically, cellular deposits (keratic precipitates) tend to be finer and distributed diffusely. <span class="italic">Granulomatous</span> inflammation also includes epithelioid and &#173;giant cells; clinically, cellular deposits with large, clumped, or greasy appearance are predominantly located in a gravity-&#173;dependent position on the inferior cornea. Discrete granulomas are characteristic of sarcoidosis and tuberculosis; diffuse granulomatous inflammation appears in Vogt-&#173;Koyanagi-&#173;Harada syndrome and sympathetic ophthalmia. Zonal granulomatous disease can be observed in lens-&#173;induced uveitis.</p>
			</div>
			<p class="h1 ParaOverride-9">Symptoms of Uveitis</p>
			<div id="Chapt5_Top5">
			<p class="body-text--no-indent-">Symptoms produced by uveitis depend on which part of the uveal tract is inflamed, the rapidity of onset (sudden or insidious), the duration of the disease (limited or per&#173;sis&#173;tent), the course of the disease (acute, chronic, or recurrent), and sometimes the under&#173;lying etiology.</p>
			<p class="body-text">Anterior uveitis can have a range of pre&#173;sen&#173;ta&#173;tions, from a quiet asymptomatic white eye to an extremely painful red eye depending on the type of uveitis and/or severity of inflammation. Sudden-&#173;onset anterior uveitis usually &#173;causes acute pain, photophobia, redness, and blurred vision. Pain results from ciliary spasm associated with inflammation in the region of the iris and may radiate over the larger area served by cranial nerve V (the trigeminal nerve). Intraocular pressure (IOP) elevation due to &#173;angle closure or trabeculitis can be another cause of pain.</p>
			<p class="body-text">In contrast, chronic anterior uveitis in patients with juvenile idiopathic arthritis (JIA) may not be associated with any symptoms at all. However, even if initially asymptomatic, chronic or severe anterior uveitis can cause blurred vision &#173;because of structural complications such as calcific band keratopathy, cataract, or macular edema.</p>
			<p class="body-text">Isolated intermediate uveitis pres&#173;ents with a white, quiet eye and produces symptoms of floaters and blurred vision. Floaters result from the shadows cast by vitreous cells and debris on the ret&#173;ina. Blurred vision can result from macular edema or vitreous opacities in the visual axis.</p>
			<p class="body-text">Presenting symptoms in patients with posterior uveitis include painless blurred vision, floaters, photopsias, scotomata, metamorphopsia, nyctalopia, or a combination of &#173;these symptoms. The blurred vision can be caused primarily by retinitis and/or choroiditis directly affecting macular function, or secondarily by complications of inflammation. Table 5-6 summarizes symptoms of uveitis.</p>
			</div>
			<p class="h1 ParaOverride-10">Signs of Uveitis</p>
			<div id="Chapt5_Top6">
			<p class="body-text--no-indent-">The chemical mediators involved in inflammation (see <span class="body-text--no-indent-_xref-local">Chapter&#160;1</span>) result in vascular dilation (ciliary flush), increased vascular permeability (aqueous flare), and chemotaxis of inflammatory cells into the eye (aqueous and vitreous cellular reaction). <span class="body-text--no-indent-_xref-table">Table&#160;5-7</span> summarizes signs of uveitis.</p>
			<p class="h2 ParaOverride-11">Anterior Segment</p>
			<p class="body-text--no-indent-">Signs of uveitis in the anterior portion of the eye include</p>
			<ul>
				<li class="bullet-list-first">inflammatory cells (<span class="bullet-list-first_xref-figure">Fig 5-1</span>)</li>
				<li class="bullet-list-mid">flare (<span class="bullet-list-mid_xref-figure">Fig 5-2</span>)</li>
				<li class="bullet-list-mid">hypopyon</li>
				<li class="bullet-list-mid">fibrin in the anterior chamber</li>
				<li class="bullet-list-mid">keratic precipitates (<span class="bullet-list-mid_xref-figure">Figs 5-3, 5-4</span>)</li>
				<li class="bullet-list-mid">iris nodules (<span class="bullet-list-mid_xref-figure">Fig 5-5</span>)</li>
				<li class="bullet-list-mid">iris atrophy or heterochromia</li>
				<li class="bullet-list-mid">pupillary miosis</li>
				<li class="bullet-list-mid">synechiae, anterior and posterior (<span class="bullet-list-mid_xref-figure">Fig 5-6</span>)</li>
				<li class="bullet-list-mid">pigment dispersion</li>
				<li class="bullet-list-mid">cataract<span class="CharOverride-2">*</span></li>
				<li class="bullet-list-last">band keratopathy<span class="CharOverride-2">*</span></li>
			</ul>
			<p class="bullet-footnotes"><span class="CharOverride-2">*</span>Observed in long-&#173;standing uveitis</p>
			<p class="body-text ParaOverride-12">The major finding in anterior uveitis is the presence of inflammatory cells and flare in&#160;the anterior chamber, but &#173;there may be many additional sequalae. The SUN system grades the intensity of anterior chamber cells according to the number of inflammatory cells observed on slit-&#173;lamp examination in a field defined as a 1 <span class="body-text_symbol">×</span> 1&#160;mm high-&#173;power beam at full intensity at a 45°–60° &#173;angle in a dark room. &#173;There are similar recommendations for grading flare. The SUN system &#173;adopted the method described previously by Hogan and colleagues (<span class="body-text_xref-table">&#173;Table&#160;5-8</span>).</p>
			<p class="body-text">The anterior chamber reaction can be described as</p>
			<ul>
				<li class="bullet-list-first">serous (aqueous flare caused by protein influx)</li>
				<li class="bullet-list-mid">purulent (polymorphonuclear leukocytes and necrotic debris causing hypopyon)</li>
				<li class="bullet-list-mid">fibrinous (plasmoid, or intense fibrinous exudate)</li>
				<li class="bullet-list-last">sanguinoid (inflammatory cells with erythrocytes, as manifested by hypopyon mixed with hyphema)</li>
			</ul>
			<p class="body-text">Keratic precipitates (KPs) are collections of inflammatory cells on the corneal endothelium. Newly formed KPs tend to be white and smoothly rounded, &#173;later transitioning to crenated (shrunken), pigmented, or glassy in nature. Large, yellowish KPs are called <span class="italic">mutton-&#173;fat KPs</span> and are usually associated with granulomatous types of inflammation. Associated corneal edema may be pres&#173;ent. Band keratopathy is seen in chronic uveitis (especially JIA associated).</p>
			<p class="body-text">Iris involvement may manifest as &#173;either anterior or posterior synechiae, iris nodules (Koeppe nodules at the pupillary border, Busacca nodules within the iris stroma (see Fig 5-5) and Berlin nodules in the &#173;angle, iris granulomas, heterochromia (eg, Fuchs uveitis syndrome), or stromal atrophy (eg, herpetic uveitis).</p>
			<p class="body-text">With uveitic involvement of the ciliary body and trabecular meshwork, IOP is often low, secondary to decreased aqueous production or increased uveoscleral outflow, but IOP may increase precipitously if the meshwork becomes clogged by inflammatory cells or debris or if the trabecular meshwork itself is the site of inflammation (trabeculitis). Pupillary block with iris bomb<span class="body-text_accent">é</span> and secondary &#173;angle closure may also lead to an acute rise in IOP.</p>
			<p class="reference--journal--single ParaOverride-6">Hogan MJ, Kimura SJ, Thygeson&#160;P. Signs and symptoms of uveitis. I. Anterior uveitis. <span class="reference--journal-_italic">Am J Ophthalmol.</span> 1959;47(5, part 2):155–170.</p>
			<p class="h2">Intermediate Segment</p>
			<p class="body-text--no-indent-">Signs of uveitis in the intermediate portion of the eye include</p>
			<ul>
				<li class="bullet-list-first">inflammatory cells in vitreous</li>
				<li class="bullet-list-mid">vitreous haze (<span class="bullet-list-mid_xref-figure">Fig 5-7</span>)</li>
				<li class="bullet-list-mid">snowballs (clumped vitreous cells)</li>
				<li class="bullet-list-mid">snowbanks (exudate over pars plana)</li>
				<li class="bullet-list-mid">ciliary body detachment</li>
				<li class="bullet-list-mid">retrolental membrane</li>
				<li class="bullet-list-last">vitreous strands or traction band</li>
			</ul>
			<p class="body-text--no-indent-">The hallmark of intermediate uveitis is vitreous cell and haze. Cells may be clumped or individual. The cells make up vitreous haze when viewed in combination with proteinaceous vitreous debris.</p>
			<p class="body-text">The physician typically grades vitreous cells on a 0–4 numeric scale by observing the retrolental space in a dilated eye using the slit-&#173;lamp biomicroscope and a 1 <span class="body-text_symbol">×</span> 0.5&#160;mm beam (<span class="body-text_xref-figure">Fig 5-8</span>). The consensus is that cells in the vitreous strands are old, and cells in the syneretic areas are likely new. The SUN system does not specify a grading system for vitreous cells. <span class="body-text_xref-table">&#173;Table&#160;5-9</span> shows the vitreous cell grading scale used in the Multicenter Uveitis Ste&#173;roid Treatment Trial (MUST).</p>
			<p class="body-text">Vitreous haze may be a better indicator of disease activity than cell counts alone. The grading of vitreous haze is based on the clarity of view of the posterior segment on funduscopic examination. The National Institutes of Health grading system for vitreous haze, which the SUN system &#173;adopted, employs a standardized set of fundus photo&#173;graphs that defines vitreous haze on a 0–4 scale (see <span class="body-text_xref-figure">Fig 5-7</span>). Vitreous haze has been used in inclusion criteria in clinical &#173;trials for uveitis, and a 2-&#173;step improvement has been used as a principal outcome mea&#173;sure.</p>
			<p class="body-text">Additional signs of inflammation in the vitreous include <span class="italic">snowball opacities</span> (clumps of inflammatory cells in the vitreous) and <span class="italic">snowbanks</span> (exudates over the pars plana, especially prominent inferiorly). Active snowbanks have a fluffy or shaggy appearance. As pars planitis becomes inactive, the pars plana appears gliotic or fibrotic and smooth; thus, &#173;these changes are not referred to as snowbanks. Vitreal strands and snowballs may vary in clinical appearance by disease type. Chronic intermediate uveitis may be associated with cyclitic membrane formation, secondary ciliary body detachment, and hypotony.</p>
			<p class="h2">Posterior Segment</p>
			<p class="h2-h2">Signs in the posterior segment of the eye include</p>
			<ul>
				<li class="bullet-list-first">ret&#173;i&#173;nal or choroidal inflammatory infiltrates</li>
				<li class="bullet-list-mid">inflammatory sheathing of arteries or veins</li>
				<li class="bullet-list-mid">exudative, tractional<span class="CharOverride-2">*</span>, or rhegmatogenous<span class="CharOverride-2">*</span> ret&#173;i&#173;nal detachment</li>
				<li class="bullet-list-mid">ret&#173;i&#173;nal pigment epithelial hypertrophy or atrophy<span class="CharOverride-2">*</span></li>
				<li class="bullet-list-mid">atrophy or swelling of the ret&#173;ina, choroid, or optic nerve head<span class="CharOverride-2">*</span></li>
				<li class="bullet-list-mid">preret&#173;i&#173;nal or subret&#173;i&#173;nal fibrosis<span class="CharOverride-2">*</span></li>
				<li class="bullet-list-last">ret&#173;i&#173;nal or choroidal neovascularization<span class="CharOverride-2">*</span></li>
			</ul>
			<p class="bullet-footnote"><span class="CharOverride-2">*</span>Indicates structural complications. Ret&#173;i&#173;nal and choroidal signs may be unifocal, multifocal, or diffuse.</p>
			<p class="body-text ParaOverride-12">Posterior segment inflammation is a result of inflammatory or infectious infiltration and resultant structural damage of the ret&#173;ina and choroid. Ret&#173;i&#173;nal and choroidal signs may be unifocal, multifocal, or diffuse. Lesions are described by size, color, and appearance (eg, well demarcated, geographic), and anatomical relationship to posterior pole landmarks (see <span class="body-text_xref-table">&#173;Table&#160;5-7</span>).</p>
			<p class="reference--journal--single ParaOverride-6">Nussenblatt RB, Palestine AG, Chan CC, Roberge&#160;F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. <span class="reference--journal-_italic">Ophthalmology.</span> 1985;92(4):467–471.</p>
			</div>
			<p class="h1 ParaOverride-13">Review of the Patient’s Health and Other Associated Factors</p>
			<div id="Chapt5_Top7">
			<p class="body-text--no-indent-">A comprehensive history and review of systems help to narrow the differential diagnosis and guide ancillary testing and treatment options. The patient’s personal characteristics, medical history, and social history can help in the classification and identification of uveitis (<span class="body-text--no-indent-_xref-table">&#173;Table&#160;5-10</span>). Immunocompromise, sexual practices, use of intravenous drugs,&#160;hyperalimenta&#173;tion, and certain occupations are just some of the risk &#173;factors that can direct the investigation. In this regard, a diagnostic survey for uveitis as shown in the appendix can be very helpful.</p>
			<p class="body-text">Although ocular inflammation can be an isolated pro&#173;cess involving only the eye, it can also be associated with a systemic condition. However, uveitis frequently does not correlate with inflammatory activity elsewhere in the body and may precede the development of inflammation at other body sites.</p>
			</div>
			<p class="h1 ParaOverride-14">Differential Diagnosis of Uveitis</p>
			<div id="Chapt5_Top8">
			<p class="body-text--no-indent-">The differential diagnosis of uveitis includes infectious agents (viruses, bacteria, fungi, protozoa, and helminths), noninfectious entities of presumed immunologic origin, and unknown/idiopathic &#173;causes (called <span class="italic">undifferentiated uveitis</span>). In addition, masquerade syndromes such as intraocular lymphoma, retinoblastoma, leukemia, choroidal metastases, and malignant melanoma can be mistaken for uveitis. Other masquerade syndromes include juvenile xanthogranuloma, pigment dispersion syndrome, ret&#173;i&#173;nal detachment, vitreous hemorrhage, retinitis pigmentosa, and ocular ischemic syndrome. One should consider all &#173;these in the differential diagnosis of uveitis.</p>
			<p class="body-text ParaOverride-15">A careful history and accurate description of biomicroscopic and fundus findings are extremely helpful in narrowing the differential diagnosis, as certain pre&#173;sen&#173;ta&#173;tions are characteristic for specific diseases; however, many patients do not pres&#173;ent with classic signs and symptoms, or their clinical appearance may evolve with time and treatment. The clinician should consider the differential diagnosis and how well the individual patient’s uveitis fits with the vari&#173;ous known entities. This system first classifies the type of uveitis based on anatomical criteria and associated &#173;factors (eg, acute versus chronic, unilateral versus bilateral, adult versus child) and then matches the pattern of uveitis with a list of potential entities that share similar characteristics. See <span class="body-text_xref-table">&#173;Table&#160;5-4</span> for a simplified version of one such system for narrowing the differential diagnosis. Activity 5-1 provides a decision-&#173;tree algorithm for the evaluation of a uveitis patient.</p>
			<p class="QR-code-caption-first ParaOverride-16"><span class="QR-code-number CharOverride-3">ACTIVITY </span><span class="QR-code-number CharOverride-3">5-1</span> <span class="body-text--no-indent-_bold">Flow chart for clinical diagnosis and treatment of uveitis: <br />simplified interactive tool</span>.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer001" class="_idGenObjectStyleOverride-2">
					<img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source ParaOverride-17">Activity developed by Thellea&#160;K. Leveque, MD, MPH.</p>
			<p class="QR-code-text-last ParaOverride-6">Access the activity at <a href="http://www.aao.org/bcscactivity_section09">www.&#173;aao.&#173;org/&#173;bcscactivity_&#173;section09</a>.</p>
			</div>
			<p class="h1 ParaOverride-14">Ancillary Testing</p>
			<div id="Chapt5_Top9">
			<p class="body-text--no-indent-">Medical history, review of systems, thorough ophthalmologic and general physical examination, and formulation of a working differential diagnosis are cornerstones of the workup of a patient with uveitis. They should precede any laboratory testing. Laboratory testing is not a substitute for a thorough, hands-on clinical evaluation.</p>
			<p class="body-text"><span class="italic">&#173;There is no one standardized battery of tests that fits for all patients with uveitis.</span> Rather, a tailored approach should be based on the most likely &#173;causes for each patient. &#173;After compiling a list of differential diagnoses, based on the anatomical location and clinical characteristics of the inflammation, the ophthalmologist can order appropriate laboratory tests. Many patients require only a few diagnostic tests.</p>
			<p class="body-text">Most uveitis specialists do recommend syphilis testing for all uveitis patients, as syphilis can pres&#173;ent as any form of uveitis, and systemic infection is often undiagnosed. In addition, the consequences of treating with ste&#173;roid in the presence of untreated occult syphilis infection can be disastrous for patient outcomes. In the correct clinical scenario, or where immunomodulatory therapy (IMT) &#173;will be used, most uveitis specialists also recommend testing for tuberculosis with a purified protein derivative (PPD) skin test or interferon-&#173;gamma release assay. A chest radiograph can screen for sarcoidosis, which is a common cause of uveitis with protean manifestations. <span class="body-text_xref-table">Tables 5-4 and 5-11</span> list some of the laboratory tests and their indications. &#173;Later chapters further discuss &#173;these tests in context of the vari&#173;ous types of uveitis.</p>
			<p class="body-text">It is impor&#173;tant to use caution in ordering and interpreting laboratory tests, &#173;because even very sensitive and specific tests are not perfect and can yield misleading results if the likelihood of disease in a par&#173;tic&#173;u&#173;lar patient is low. In other words, when testing a large group of patients for a very rare disease, a positive test may not actually represent the true presence of disease. The Bayes theorem describes this concept. The theorem is a statistical calculation used to describe the probability of an event based on prior knowledge of conditions that might be related to the event. (See BCSC Section&#160;1, <span class="italic">Update on General Medicine.)</span></p>
			<p class="h2 ParaOverride-18">Ophthalmic Imaging and Functional Tests</p>
			<p class="body-text--no-indent-">Ophthalmic imaging and functional testing are useful both diagnostically and in monitoring the patient’s response to therapy. They can provide information not obtainable from biomicroscopic or fundus examination. The use of combined imaging modalities, called <span class="italic">multimodal imaging</span>, can be complementary and additive in this task. For discussion of ophthalmic imaging modalities and electroretinogram testing, see BCSC Section&#160;12, <span class="italic">Ret&#173;ina and Vitreous</span>.</p>
			<p class="reference--journal--first">Kawali A, Pichi F, Avadhani K, Invernizzi A, Hashimoto Y, Mahendradas P. Multimodal imaging of the normal eye. <span class="reference--journal-_italic">Ocul Immunol Inflam.</span> 2017;25(5):721–731.</p>
			<p class="reference--journal--mid">Van Gelder RN. Diagnostic testing in uveitis. <span class="reference--journal-_italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Academy of Ophthalmology; 2013, module 4.</p>
			<p class="h3 ParaOverride-19">Optical coherence tomography</p>
			<p class="body-text--no-indent-">Optical coherence tomography (OCT) produces a series of high-&#173;resolution cross-&#173;sectional images of the ret&#173;ina and choroid and is used to identify morphologic changes seen in eyes with uveitis. A noncontact imaging technique, OCT has become the standard-&#173;of-&#173;care method for objective mea&#173;sure&#173;ment of uveitic macular edema (<span class="body-text--no-indent-_xref-figure">Fig 5-9</span>), ret&#173;i&#173;nal thickening, subret&#173;i&#173;nal and intraret&#173;i&#173;nal fluid associated with choroidal neovascularization, and serous ret&#173;i&#173;nal detachments. Although sometimes useful in viewing the fundus in eyes with smaller pupils, Media opacity can limit the clarity of OCT. OCT is also valuable in monitoring the nerve fiber layer in patients with uveitic glaucoma. Anterior segment OCT may be useful to evaluate an eye for retained lens fragments or IOL chafing in per&#173;sis&#173;tent postoperative uveitis. &#173;There are ongoing efforts to develop OCT-&#173;based objective grading of intraocular cells/inflammation.</p>
			<p class="body-text">Enhanced depth imaging OCT (EDI-&#173;OCT; <span class="body-text_xref-figure">Fig 5-10</span>) provides deeper tissue penetration. This technique allows visualization of the choroid, which can have structural alterations in several uveitic diseases, notably Vogt-&#173;Koyanagi-&#173;Harada syndrome, sympathetic ophthalmia, and birdshot chorioretinopathy.</p>
			<p class="body-text">OCT angiography (OCT-&#173;A) relies on repeated high-&#173;resolution scans of the same area to assess differences in blood flow, producing structural images of perfused vessels in ocular tissues. Case reports and case series describing the OCT-&#173;A characteristics of active and inactive chorioret&#173;i&#173;nal lesions are emerging. &#173;These &#173;will have increasing implications for diagnosis and treatment of posterior uveitides over time.</p>
			<p class="reference--journal--first">Kim J, Knickelbein J, Jaworski L, et al. Enhanced depth imaging optical coherence tomography in uveitis: an intravisit and interobserver reproducibility study. <br /><span class="reference--journal-_italic">Am J Ophthalmol</span>. 2016;164:49–56.</p>
			<p class="reference--journal--mid">Pichi F, Sarraf D, Arepalli S, et al. The application of optical coherence tomography angiography in uveitis and inflammatory eye diseases. <span class="reference--journal-_italic">Prog Retin Eye Res.</span> 2017;59:178–201.</p>
			<p class="h3">Fluorescein angiography</p>
			<p class="body-text--no-indent-">Fluorescein angiography is an essential imaging modality for evaluating eyes with chorioret&#173;i&#173;nal disease and structural complications caused by posterior uveitis. &#173;After intravenous injection of fluorescein sodium, a series of filtered posterior segment images provides a functional and structural view of ret&#173;i&#173;nal (and to some degree choroidal) vasculature and anatomy. Fluorescein angiography can detect macular edema (<span class="body-text--no-indent-_xref-figure">Fig 5-11</span>), ret&#173;i&#173;nal vasculitis, secondary choroidal or ret&#173;i&#173;nal neovascularization, and areas of optic nerve, ret&#173;i&#173;nal, and choroidal inflammation. Several of the retinochoroidopathies, or white dot syndromes, have characteristic appearances on FA. Wide and ultra-&#173;wide-&#173;field FA can identify ret&#173;i&#173;nal vascular pathology not noted on clinical examination.</p>
			<p class="reference--journal--first">Laovirojjanakul W, Acharya N, Gonzales JA. Ultra-widefield fluorescein angiography in intermediate uveitis. <span class="reference--journal-_italic">Ocul Immunol Inflam.</span> 2017 Oct 17:1–6.</p>
			<p class="h3">Color photography</p>
			<p class="body-text--no-indent-">Used alone or in conjunction with other imaging, color photo&#173;graphs of the anterior or posterior segment document lesion size, color, location, and morphologic characteristics used to assess clinical progression or regression of disease. &#173;These images can be useful in establishing a baseline when assessing a relapsing and remitting inflammatory pro&#173;cess (eg, the presence of new posterior synechiae in anterior uveitis, or capturing transitory posterior segment inflammation characteristic of Beh<span class="body-text--no-indent-_accent">ç</span>et disease).</p>
			<p class="h3">Fundus autofluorescence</p>
			<p class="body-text--no-indent-">Fundus autofluorescence (FAF) imaging is another noninvasive imaging technique for analyzing the posterior segment. It maps the fluo&#173;rescent property of lipofuscin, a breakdown product of ret&#173;i&#173;nal proteins, within the ret&#173;i&#173;nal pigment epithelium (RPE). Hyperautofluorescence corresponds to increased metabolic activity of the RPE, or win&#173;dow defect due to loss of photoreceptors. Hypoautofluorescence occurs with loss or blockage of RPE cells. Imaging is useful in posterior uveitis that involves the outer ret&#173;ina, RPE, and inner choroid. Autofluorescence patterns vary between the dif&#173;fer&#173;ent uveitides, but in many cases, hyperautofluorescence occurs with increased disease activity and fades and darkens as the inflammation subsides.</p>
			<p class="h3">Indocyanine green angiography</p>
			<p class="body-text--no-indent-">Like FA, indocyanine green (ICG) imaging uses an intravenous injection coupled with serial ret&#173;i&#173;nal images to provide data about vasculature and anatomy of the posterior segment; the properties of ICG allow for specialized imaging of the choroidal circulation. In inflammatory diseases involving the outer ret&#173;ina and choroid, findings on ICG often exceed &#173;those vis&#173;i&#173;ble on &#173;either fundoscopy or FA, which can have diagnostic and therapeutic implications. Its use is especially beneficial in the evaluation of inflammatory chorioretinopathies of unknown etiology (white dot syndromes), Vogt-&#173;Koyanagi-&#173;Harada syndrome, sympathetic ophthalmia, and posterior segment sarcoidosis, and in evaluation of choroidal neovascular membrane (see <span class="body-text--no-indent-_xref-local">Chapter&#160;9</span>).</p>
			<p class="h3">Ultrasonography</p>
			<p class="body-text--no-indent-">Anterior segment ultrasound biomicroscopy can be useful in diagnosing pathology of the ciliary body, iris, and iridocorneal &#173;angle in uveitis. Posterior segment ultrasound, or B-&#173;scan ultrasound, can be useful in demonstrating vitreous opacities, choroidal thickening or elevation, ret&#173;i&#173;nal detachment, and cyclitic membrane formation, as well as in ruling out occult foreign bodies, particularly if media opacities preclude a view of the posterior segment. Retained IOL fragments may be visualized in the anterior or posterior segment. Ultrasonographic imaging may be diagnostic for posterior scleritis (see <span class="body-text--no-indent-_xref-local">Chapter&#160;7</span>).</p>
			<p class="h3">Electroretinography</p>
			<p class="body-text--no-indent-">Full-field electroretinography (ERG) can be used to monitor progression of birdshot chorioretinopathy, diagnose acute zonal occult outer retinopathy (AZOOR) complex diseases, and diagnose autoimmune retinopathy. Electroretinogram findings may also be useful in the uveitis workup when trying to distinguish certain ret&#173;i&#173;nal dystrophies from posterior uveitis.</p>
			<p class="h3">Visual field testing/perimetry</p>
			<p class="body-text--no-indent-">Kinetic and nonkinetic perimetry are used to monitor progression and response to treatment of birdshot chorioretinopathy and AZOOR complex diseases. &#173;These techniques are also used to monitor visual field defects in uveitic glaucoma or inflammatory optic neuritis. Microperimetry may be helpful in diseases involving the macula, such as punctate inner choroiditis.</p>
			<p class="h2 ParaOverride-19">Ocular Fluid and Tissue Sampling</p>
			<p class="h3-h2">Polymerase chain reaction testing of aqueous and vitreous fluid</p>
			<p class="body-text--no-indent-">Polymerase chain reaction (PCR) testing for diagnosis of infectious uveitis is highly sensitive and specific. It can directly amplify the DNA of a suspected pathogen from a small sample volume of ophthalmic fluid, making it ideal for application in ocular tissue.</p>
			<p class="body-text">Testing of aqueous fluid is an impor&#173;tant adjunct in diagnosis of infectious posterior uveitis. Aqueous humor PCR testing that is specific for herpes simplex virus types 1 or 2, varicella-&#173;zoster virus, and cytomegalovirus has high diagnostic sensitivity and specificity at levels similar to vitreous biopsy. Anterior chamber paracentesis is generally safer and easier to perform than vitreous sampling. In suspected cases of ret&#173;i&#173;nal toxoplasmosis, one can perform anterior chamber paracentesis for PCR, though the diagnostic yield may be lower than vitreous sampling. In toxoplasmosis, a positive anterior chamber PCR result can be more likely in patients with large lesions or immunocompromised patients. Diagnostic utility of isolated aqueous PCR testing for suspected viral anterior uveitis is much lower. In cases for which viral speciation is critical to management, repeat sampling can increase the yield.</p>
			<p class="body-text">&#173;Until recently, PCR was not practical for diagnosis of bacterial and fungal uveitis due to the need to specify the selected pathogen of interest for amplification. Now, based on conserved ge&#173;ne&#173;tic subunits within bacteria (16S) and fungi (5.8S/18S/28S), panbacterial and panfungal PCR tests perform equally or superiorly to culture. The PCR-&#173;based techniques for genomic testing of vitreous samples are used in diagnosis of primary intraocular lymphoma. Disadvantages of PCR are cost, limitations in testing for multiple entities due to small fluid sample size, risk of improper amplification of a contaminant, and risk of identification failure when &#173;there is a paucity of cellular material.</p>
			<p class="reference--journal--first">Doan T, Acharya N, Pinsky BA, et al. Metagenomic DNA sequencing for the diagnosis of intraocular infections. <span class="reference--journal-_italic">Ophthalmology.</span> 2017;124(8):1247–1248.</p>
			<p class="reference--journal--mid">Harper TW, Miller D, Schiffman JC, Davis JL. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. <span class="reference--journal-_italic">Am J Ophthalmol</span>. 2009;147(1):140–147.</p>
			<p class="reference--journal--mid">Rothova A, de Boer JH, Ten Dam-van Loon NH, et al Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. <span class="reference--journal-_italic">Ophthalmology.</span> 2008;115(2):306–311.</p>
			<p class="reference--journal--mid">Sowmya P, Madhavan HN. Diagnostic utility of polymerase chain reaction on intraocular specimens to establish the etiology of infectious endophthalmitis. <span class="reference--journal-_italic">Eur J Ophthalmol.</span> 2009;19(5):812–817.</p>
			<p class="reference--journal--last">Taravati P, Lam D,Van Gelder RN. Role of molecular diagnostics in ocular microbiology. <br /><span class="reference--journal-_italic">Curr Ophthalmol Rep.</span> 2013;1(4).</p>
			<p class="h3 ParaOverride-20">Ocular serology/local antibody production</p>
			<p class="body-text--no-indent-">Eu&#173;ro&#173;pean countries consider evaluation of aqueous antibody production based on the Goldmann-&#173;Witmer (GW) coefficient as the gold standard for the diagnosis of toxoplasmosis; however, this not commercially available in the United States. (Chapter&#160;2 explained calculation of the GW.) Diagnostic yield may increase when PCR and the GW coefficient are used together, especially in viral infections. Aqueous antibody production may persist even in the absence of cellular material, giving it certain advantages over PCR in viral anterior uveitis.</p>
			<p class="h3 ParaOverride-20">Culture and vital staining</p>
			<p class="body-text--no-indent-">Cell culture and bacterial and fungal staining are useful in cases of suspected bacterial or fungal endophthalmitis. Isolation is time consuming and can lack sensitivity due to the low pathogen load in ocular samples. However, the technique is the traditional first line of testing, widely available, and inexpensive to perform.</p>
			<p class="h2 ParaOverride-13">Cytology and Pathology</p>
			<p class="body-text--no-indent-">Anterior chamber paracentesis for cytologic studies may be diagnostic in cases involving the anterior or sometimes the posterior segment. Anterior chamber paracentesis in suspected leukemia or lymphoma is sent for cytologic analy&#173;sis. When &#173;there is concern for primary vitreoret&#173;i&#173;nal lymphoma, undiluted vitreous biopsy fluid is sent for cytology and flow cytometry analy&#173;sis with gene rearrangement studies and cytokine analysis.</p>
			<p class="body-text">Chorioret&#173;i&#173;nal biopsy for pathology is technically challenging and calls for an experienced vitreoret&#173;i&#173;nal surgeon. It may be useful in rapidly progressive posterior uveitic entities for which the etiology is unknown and the therapeutic regimen undetermined. Suspected intraocular lymphoma confined to the subret&#173;i&#173;nal space is also an indication for a chorioret&#173;i&#173;nal biopsy. It is usually performed only if diagnosis cannot be confirmed &#173;after all other less-&#173;invasive testing. Directed conjunctival biopsy of vis&#173;i&#173;ble lesions can be useful in lymphoma, cicatricial pemphigoid, and sarcoidosis. Rarely, scleral biopsy can be useful when considering infectious etiologies for scleritis (see <span class="body-text_xref-local">Chapter&#160;7</span>). Vitreous biopsy can also be done to identify the etiology of certain uveitides, particularly in suspected cases of infectious chorioretinitis.</p>
			<p class="h3 ParaOverride-21">Anterior chamber paracentesis technique</p>
			<p class="body-text--no-indent-">Paracentesis involves using sterile technique at the slit lamp or with the patient supine on a treatment gurney or chair. Topical anesthetic drops are instilled; the eye is prepared with topical povidone-&#173;iodine solution; and a lid speculum can be placed. A tuberculin (1-&#173;mL) syringe is attached to a sterile 30-&#173;gauge needle. The syringe is then advanced &#173;under direct or slit-&#173;lamp visualization into the anterior chamber through the temporal limbus or clear cornea parallel to the iris plane. As much aqueous is aspirated as is safely pos&#173;si&#173;ble (usually 0.1–0.2&#160;mL), avoiding contact with the iris and lens. Pos&#173;si&#173;ble complications include anterior chamber bleeding, infection, and damage to the iris or lens.</p>
			<p class="h3 ParaOverride-21">Vitreous biopsy technique</p>
			<p class="body-text--no-indent-">Vitreous specimens can be obtained &#173;either by needle tap or by using a vitrectomy instrument. If a small sample is desired, a needle tap of the vitreous is typically performed with the patient partially reclining in an examination room chair. Topical and subconjunctival anesthesia are administered; the eye is prepared with topical povidone-&#173;iodine solution, and a lid speculum is placed. Typically, a 25-&#173;gauge, 1-&#173;inch needle on a 3mL syringe (to provide greater vacuum) is introduced through the pars plana, directed &#173;toward the midvitreous cavity, and used to aspirate the vitreous sample. A diagnostic vitrectomy is performed via a standard 3-&#173;port pars plana vitrectomy (see BCSC Section&#160;12, <span class="italic">Ret&#173;ina and Vitreous</span>). The most common indications for vitreous biopsy include suspected infection, primary intraocular lymphoma or other intraocular malignancy, and infectious etiologies of posterior uveitis or panuveitis. (Endophthalmitis is discussed in detail in <span class="body-text--no-indent-_xref-local">Chapter&#160;12</span>, and intraocular lymphoma in <span class="body-text--no-indent-_xref-local">Chapter&#160;13</span>.). In addition, chronic uveitis that has an aty&#173;pi&#173;cal&#160;pre&#173;sen&#173;ta&#173;tion or an inadequate response to conventional therapy may warrant diagnostic vitrectomy.</p>
			<p class="body-text">In all &#173;these scenarios, testing typically requires undiluted vitreous specimens. It is pos&#173;si&#173;ble to obtain 0.5–1.0&#160;mL of undiluted vitreous for evaluation using standard vitrectomy techniques. Complications of diagnostic vitrectomy in uveitic eyes can include ret&#173;i&#173;nal tears or detachment, suprachoroidal or vitreous hemorrhage, worsening of cataract or inflammation, and, rarely, sympathetic ophthalmia. Although vitreous surgery can be therapeutic and diagnostic in cases of uveitis, the pharmacokinetics of delivered intravitreal drugs are markedly altered in eyes that have under&#173;gone pars plana vitrectomy; the half-&#173;life of intravitreal corticosteroids, for example, is significantly reduced in vitrectomized eyes.</p>
			<p class="h3">Chorioret&#173;i&#173;nal biopsy technique</p>
			<p class="body-text--no-indent-">Video 5-1 demonstrates chorioret&#173;i&#173;nal biopsy.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-2">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/qrcode_BCSC2019_S09_Video05-01.png" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"><span class="QR-code-number">VIDEO 5-1</span> Chorioretinal biopsy.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source"><span class="qr-code-source_italic">Courtesy of P. Kumar Rao, MD.</span></p>
			<p class="QR-code-text-last">Access the video at <a href="http://www.aao.org/bcscvideo_section09">www.&#173;aao.&#173;org/&#173;bcscvideo_&#173;section09</a>.</p>
		</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACAAAAArCAYAAAAZvYo3AAAACXBIWXMAABcRAAAXEQHKJvM/AAADsUlEQVRYR+WWa0hTYRiAFxVUP/oVEQRF/XDiTGeWCYtCSKHES95QNhGRLCi8LOyiLC9/IssfOvOHwqwRmqSoIalrYJJaeWk5E3XmxGALMzei0DV1b+c7dWJnO2ffcRf3oxceOBvnvO9zvvc73/fxAIBHw2Q4Ck2322ncvbAEMhE40Zinpt33tu2qUz4MDsWNR0D7Mp2xGBeabrWDURcGG2s7cYWZBZpLWrFFuPBj+QCuMF3g+9eD8OTmc6iMN2KTc+FxYS+MdOTiiv8RQMM+2ZeMTbpZWmRPwTB1Amwb210LtFYosck8wfJzr8cCDxKEcOlssBMGaeTWCEhOCyA8PBxSU1NJYmJiICAgAHR5p7ZOIDs7G6hQq9VeFKhMMOCS+FYAl8BTgU/D0WD+cth/Aojeunv/sUD95SEYbr/iPwHsJHxUoMIl8a2A39cBvwssLfDhQ4/E6wLNxW0wrzkDG+uY3RBdIAk3BJ6Jw2Eo9yQj+ub7cleFvSLgioqKik0IWC27YUErAsW1Pi4CZrMZxsbGWImIiACRSGRMT08fsGd93bkddKO+Rhl5nELYnYQdBXBRUFBA3k9Bbd/9/f3nBwYGYgYHB88Bo4A9yusv3BVwjPr6elp7BALBL7ATuGMwGN6kpaXReK/qyIbPHyMRktSLY54ILC4ugkajISkuLgY+n29DNTo7O8W86elpZUtLC2mWmJgIRK/I69raWhkaMkRcXJzWEwH7IIpCTk4OWaOhoaGIV1RUpKSGpqenByYnJxlntbcEUFitVnaBlZUV0Gq1Tuj1elxezkETUCgU0szMzD70R1VVFYyMjOCe9zhoAsRvHvF2fGoU0DzwdTgJWCyWXUTvj2dlZalDQkJICbSg+CqcBCiI7/WGRCIh21FdXe2TdszNzZFzjVEAQYxEGNUO9El6O2pqav59WYwCq6uru6empkIzMjJeh4aGQnx8PExMTLjOuolAAkFBQVZUY3l5eT/rUlxXV1dCtOPV30UJRkdHXeXlFCqVCvLz852WYlaIiSjy5kJEvDnjXsAKsSjt0el0wcnJycNCoRBiY2NhZmaGtQAukEBZWdnD2dlZAXARoCD6VioWi/uR/fj4OEt69kAzv7u7GwIDA0Eul5eCXW5scQpiH492V8B+O/ZYICoqCsrLy5nqsAYlQLQv2GQy7QN3BIiHjxUWFjYTx61vSUlJ0NXVxRmpVEoKrK2t7XDMiy3sSEpKyjum7ZoLXhEwGo2H5ufnA9zBZrNtc8z3G754AdruumoZAAAAAElFTkSuQmCC" alt="" />
			</div>
		</div>
		<div id="_idContainer007" class="Basic-Text-Frame">
			<table id="table001" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-3" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-4" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="5">
							<p class="table-title"><span class="table-number">Table 5-1</span> Anatomical Classification of Uveitis Based on Standardization of Uveitis Nomenclature (SUN) Criteria</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Type </p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Primary Site of Inflammation</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Includes</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Anterior uveitis</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Anterior chamber</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Iritis</p>
							<p class="table-body">Iridocyclitis</p>
							<p class="table-body">Anterior cyclitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Intermediate uveitis</p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Vitreous</p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Pars planitis</p>
							<p class="table-body">Posterior cyclitis</p>
							<p class="table-body">Hyalitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-9">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Posterior uveitis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Retina or choroid</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span lang="fr-FR">Focal, multifocal, or diffuse choroiditis</span></p>
							<p class="table-body"><span lang="fr-FR">Chorioretinitis</span></p>
							<p class="table-body">Retinochoroiditis</p>
							<p class="table-body">Retinitis</p>
							<p class="table-body">Neuroretinitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Panuveitis</p>
						</td>
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Anterior chamber, vitreous, and retina or choroid</p>
						</td>
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-7" colspan="5">
							<p class="table-source-note">Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of nomenclature for reporting clinical data. Results of the First International Workshop. <span class="table-source-emphasis">Am J Ophthalmol.</span> 2005;140(3):510.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer008" class="Basic-Text-Frame">
			<table id="table002" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-14" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="5">
							<p class="table-title"><span class="table-number">Table 5-2</span> Descriptors of Uveitis Based on Standardization of Uveitis Nomenclature (SUN) Criteria</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Category</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Descriptor</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Comment</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Onset</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Sudden</p>
							<p class="table-body">Insidious</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body ParaOverride-22">Duration</p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body ParaOverride-22">Limited</p>
							<p class="table-body">Persistent</p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body ParaOverride-22"><span class="CharOverride-4">≤</span>3 months’ duration</p>
							<p class="table-body">&gt;3 months’ duration</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body ParaOverride-22">Course</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body ParaOverride-22">Acute</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body ParaOverride-22">Episode characterized by sudden onset and limited duration</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-18">
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Recurrent</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Repeated episodes separated by periods of inactivity without treatment <span class="CharOverride-4">≥</span>3 months’ duration</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9">
							<p class="table-body">Chronic</p>
						</td>
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9">
							<p class="table-body">Persistent uveitis with relapse in &lt;3 months after discontinuing treatment</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-19">
						<td class="No-Table-Style CellOverride-7" colspan="5">
							<p class="table-source-note">Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of nomenclature for reporting clinical data. Results of the First International Workshop.<span class="table-source-emphasis"> Am J Ophthalmol.</span> 2005;140(3):511.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer009" class="Basic-Text-Frame">
			<table id="table003" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-20" />
					<col class="_idGenTableRowColumn-21" />
					<col class="_idGenTableRowColumn-22" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 5-3</span> Uveitis Terminology Based on Standardization of Uveitis Nomenclature (SUN) Criteria </p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Term</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Definition</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-23">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Inactive</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Grade 0 cells (anterior chamber)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Worsening activity</p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Two-step increase in level of inflammation (eg, anterior chamber cells, vitreous haze) or increase from grade 3+ to 4+</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Improved activity</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Two-step decrease in level of inflammation (eg, anterior chamber cells, vitreous haze) or decrease to grade 0</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Remission</p>
						</td>
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Inactive disease for <span class="CharOverride-4">≥</span>3 months after discontinuing all treatments for eye disease</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-7" colspan="3">
							<p class="table-source-note">Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of nomenclature for reporting clinical data. Results of the First International Workshop. <span class="CharOverride-5">Am J Ophthalmol.</span> 2005;140(3):513.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer012">
				<div id="_idContainer010" class="Basic-Text-Frame">
					<table id="table004" class="No-Table-Style">
						<colgroup>
							<col class="_idGenTableRowColumn-24" />
							<col class="_idGenTableRowColumn-25" />
							<col class="_idGenTableRowColumn-26" />
							<col class="_idGenTableRowColumn-25" />
							<col class="_idGenTableRowColumn-27" />
							<col class="_idGenTableRowColumn-25" />
							<col class="_idGenTableRowColumn-28" />
						</colgroup>
						<thead>
							<tr class="No-Table-Style _idGenTableRowColumn-29">
								<td class="No-Table-Style TT" colspan="7">
									<p class="TT"><span class="table-number">&#173;Table&#160;5-4</span> Simplified Scheme for Patient Evaluation in Uveitis</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-16">
								<td class="No-Table-Style TCH CellOverride-10">
									<p class="table-column-head">Type of Inflammation</p>
								</td>
								<td class="No-Table-Style TCH CellOverride-10" />
								<td class="No-Table-Style TCH CellOverride-10">
									<p class="table-column-head">Pos&#173;si&#173;ble Associated &#173;Factors</p>
								</td>
								<td class="No-Table-Style TCH CellOverride-10" />
								<td class="No-Table-Style TCH CellOverride-10">
									<p class="table-column-head">Suspected Disease<span class="table-column-head_superscript _idGenCharOverride-1">a</span></p>
								</td>
								<td class="No-Table-Style TCH CellOverride-10" />
								<td class="No-Table-Style TCH CellOverride-10">
									<p class="table-column-head">Laboratory Tests, Imaging</p>
								</td>
							</tr>
						</thead>
						<tbody>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TBF CellOverride-11 _idGenCellOverride-1" colspan="7">
									<p class="table-subhead">Panuveitis</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-15">
								<td class="No-Table-Style TB CellOverride-12" colspan="7">
									<p class="table-body">See entities described below: sarcoidosis, Vogt-Koyanagi-Harada syndrome, sympathetic ophthalmia, Beh<span class="table-body_accent">ç</span>et disease, syphilis, toxoplasmosis, endophthalmitis, toxocariasis, cysticercosis</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-29">
								<td class="No-Table-Style TBF CellOverride-13 _idGenCellOverride-1" colspan="7">
									<p class="table-subhead">Anterior Uveitis</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-31">
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Acute/sudden onset, severe with or without fibrin membrane or hypopyon</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Arthritis, back pain, GI/GU symptoms</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Seronegative spondyloarthropathies (ankylosing spondylitis, reactive arthritis, inflammatory bowel disease, psoriatic arthritis)</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">HLA-&#173;B27; sacro&#173;iliac films; rheumatology, gastroenterology referrals</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Oral and genital ulcers, skin findings</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Beh<span class="table-body_accent">ç</span>et disease</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Clinical diagnosis, screen for other organ involvement; rheumatology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Febrile illness, flank or abdominal pain</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Tubulointerstitial nephritis and uveitis (TINU) syndrome</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Renal function tests, urinalysis, urine beta<span class="table-body_subscript _idGenCharOverride-1">2</span>-&#173;microglobulin; nephrology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-33">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Postsurgical or penetrating eye trauma, or systemic indwelling lines/instrumentation/infection</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Infectious endophthalmitis, toxic anterior segment syndrome</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">B-&#173;scan for vitritis, consider vitreous culture, vitrectomy. For endogenous consider blood cultures and systemic infectious workup.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">None</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Undifferentiated (idiopathic)</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">HLA-&#173;B27</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-16">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Moderate severity (red, painful)</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Shortness of breath, skin findings, granulomatous inflammation </p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Sarcoidosis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">ACE, lysozyme; CXR; chest CT or gallium scan; biopsy</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Blunt eye trauma</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Traumatic iritis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Increased IOP</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Glaucomatocyclitic crisis, herpetic iritis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Clinical diagnosis; PCR of ocular fluid<span class="table-body_superscript _idGenCharOverride-1">b</span> optional</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Poor response to ste&#173;roids</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Syphilis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Syphilis IgG or FTA-&#173;ABS or MHA-&#173;TP followed by RPR or VDRL</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-5">
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL">
									<p class="table-body">Postsurgical</p>
								</td>
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL">
									<p class="table-body">Low-&#173;grade endophthalmitis (eg, <span class="table-body_italic">Propionibacterium acnes</span>); IOL-&#173;related</p>
								</td>
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL">
									<p class="table-body">Consider vitrectomy, capsulectomy with culture</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-29">
								<td class="No-Table-Style TBF CellOverride-13 _idGenCellOverride-1" colspan="7">
									<p class="table-subhead">Anterior Uveitis (continued)</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-16">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Chronic; minimal redness, pain</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Child, especially with arthritis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">JIA-&#173;related anterior uveitis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">ANA, ESR, RF; rheumatology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-34">
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Heterochromia or small nodules, diffuse KP, unilateral</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Fuchs uveitis syndrome</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Clinical diagnosis; rubella virus antibody where available</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-34">
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Postsurgical</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Low-&#173;grade endophthalmitis <br />(eg, <span class="table-body_italic">Propionibacterium acnes</span>); IOL-&#173;related</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Consider vitrectomy, capsulectomy with culture</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">None</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Undifferentiated</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-11" colspan="7">
									<p class="table-subhead"><span class="table-head_bold">Intermediate Uveitis</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-16">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Mild to moderate</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Shortness of breath, skin findings, granulomatous inflammation</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Sarcoidosis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">ACE, lysozyme; CXR/chest CT or gallium scan; biopsy</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Tick exposure, erythema chronicum migrans rash, endemic area</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Lyme disease (can also be anterior, <br />posterior/panuveitis)</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">ELISA, Western blot for confirmation</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Neurologic symptoms</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Multiple sclerosis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">MRI of brain and c-&#173;spine; LP for oligoclonal bands; neurology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Over age 50&#160;years</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Intraocular lymphoma</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Vitrectomy; chorioret&#173;i&#173;nal biopsy; cytology; IL-10/IL-6 ratio<span class="table-body_superscript _idGenCharOverride-1">b</span>; genotyping studies; brain MRI, LP</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">None</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Pars planitis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-11" colspan="7">
									<p class="table-subhead"><span class="table-head_bold">Posterior Uveitis</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-35">
								<td class="No-Table-Style TB" colspan="7">
									<p class="table-head"><span class="table-head_bold">Chorioretinitis with vitritis</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Focal</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Adjacent scar; raw meat, unwashed vegetable ingestion, endemic area</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Toxoplasmosis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Clinical diagnosis; negative serology to rule out the diagnosis; PCR of ocular fluid<span class="table-body_superscript _idGenCharOverride-1">b</span> optional</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Child; history of geophagia</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Toxocariasis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Clinical diagnosis; ELISA, complete blood count with differential</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">HIV infection or immunosuppressed </p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">CMV retinitis (variable vitritis)</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">PCR of ocular fluid<span class="table-body_superscript _idGenCharOverride-1">b</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Multifocal</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Shortness of breath, skin findings <br />Endemic area</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Sarcoidosis</p>
									<p class="table-body">Tuberculosis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">ACE, lysozyme; CXR/chest CT or gallium scan</p>
									<p class="table-body">IGRA or PPD, chest x-&#173;ray/chest CT</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16">
									<p class="table-body">Peripheral ret&#173;i&#173;nal necrosis with occlusive arteriolar vasculitis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16">
									<p class="table-body">ARN</p>
								</td>
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16">
									<p class="table-body">PCR of ocular fluid<span class="table-body_superscript _idGenCharOverride-1">b</span>, possibly vitrectomy/ret&#173;i&#173;nal biopsy</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-17" colspan="7">
									<p class="table-subhead"><span class="table-head_bold">Posterior Uveitis (continued)</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-19">
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">HIV infection or immunosuppressed</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Syphilis, toxoplasmosis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-14" />
								<td class="No-Table-Style TB CellOverride-14">
									<p class="table-body">Syphilis IgG or FTA-&#173;ABS or MHA-&#173;TP and RPR or VDRL; toxoplasmosis ELISA to rule out</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">IV drug use, indwelling lines</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body"><span class="table-body_italic">Candida, Aspergillus</span> infection</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Blood, vitreous cultures</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Vis&#173;i&#173;ble intraocular parasite; from Africa or Central/South Amer&#173;i&#173;ca</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Cysticercosis</p>
									<p class="table-body">Onchocerciasis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">ELISA, brain MRI</p>
									<p class="table-body">Skin snip</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Over age 50&#160;years</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Intraocular lymphoma</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Vitrectomy; chorioret&#173;i&#173;nal biopsy cytology; IL-10/IL-6 ratio<span class="table-body_superscript _idGenCharOverride-1">b</span> genotyping studies; brain MRI, LP</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">None</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Birdshot chorioretinopathy</p>
									<p class="table-body">Multifocal choroiditis with panuveitis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Clinical diagnosis; HLA-&#173;A29</p>
									<p class="table-body">Rule out TB, sarcoidosis, syphilis</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style TB">
									<p class="table-body">Diffuse</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Dermatologic/CNS symptoms; serous retinal disease</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Vogt-Koyanagi-Harada syndrome</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Clinical diagnosis; LP to document CSF pleocytosis; consider audiology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Postsurgical/traumatic, bilateral, serous retinal disease</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Sympathetic ophthalmia</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Postsurgical/traumatic, unilateral</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Infectious endophthalmitis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Consider vitrectomy, culture</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Child; history of geophagia</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Toxocariasis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">ELISA, complete blood count with differential</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-18" colspan="7">
									<p class="table-head"><span class="table-head_bold">Chorioretinitis</span> <span class="table-head_italic_bold">without</span> <span class="table-head_bold">vitritis</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Focal</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">None; history of carcinoma</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Neoplastic</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Metastatic workup</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Multifocal</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Ohio/Mississippi Valley</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Ocular histoplasmosis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Clinical diagnosis</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Lesions confined to posterior pole</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">White dot syndromes (eg, APMPPE, <br />MEWDS, PIC)</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Clinical diagnosis</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Geographic (maplike) pattern of scars</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Serpiginous choroiditis</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">IGRA or PPD, CXR</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Diffuse</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">From Africa, Central/South Amer&#173;i&#173;ca</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Onchocerciasis</p>
								</td>
								<td class="No-Table-Style TB CellOverride-15" />
								<td class="No-Table-Style TB CellOverride-15">
									<p class="table-body">Skin snip</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16">
									<p class="table-body">Severe immunocompromise <br />(eg, AIDS)</p>
								</td>
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16">
									<p class="table-body">Progressive outer ret&#173;i&#173;nal necrosis </p>
								</td>
								<td class="No-Table-Style TB CellOverride-16" />
								<td class="No-Table-Style TB CellOverride-16">
									<p class="table-body">Same as for ARN</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-30">
								<td class="No-Table-Style TB CellOverride-17" colspan="7">
									<p class="table-subhead"><span class="table-head_bold">Posterior Uveitis (continued)</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-17">
								<td class="No-Table-Style TB CellOverride-15" colspan="7">
									<p class="table-head"><span class="table-head_bold">Vasculitis</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Aphthous ulcers, hypopyon</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Beh<span class="table-body_accent">ç</span>et disease</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Clinical diagnosis, screen for other organ involvement; rheumatology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-18">
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Malar rash, female, arthralgias</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">Systemic lupus erythematosus</p>
								</td>
								<td class="No-Table-Style TB" />
								<td class="No-Table-Style TB">
									<p class="table-body">ANA, anti-dsDNA, C3, C4; rheumatology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-36">
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL">
									<p class="table-body">Chronic sinusitis with hemorrhagic rhinorrhea, dyspnea, renal insufficiency, purpura</p>
								</td>
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL">
									<p class="table-body">Granulomatosis with polyangiitis</p>
								</td>
								<td class="No-Table-Style TBL" />
								<td class="No-Table-Style TBL">
									<p class="table-body">c-&#173;ANCA (anti–&#173;proteinase 3); rheumatology referral</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-37">
								<td class="No-Table-Style TFN" colspan="7">
									<p class="table-footnote"><span class="table-footnote_superscript _idGenCharOverride-1">a</span> Syphilis may pres&#173;ent as any type of uveitis and should be considered in all patients.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-38">
								<td class="No-Table-Style TFN CellOverride-19 _idGenCellOverride-2" colspan="7">
									<p class="table-footnote"><span class="table-footnote_superscript _idGenCharOverride-1">b</span> Testing where available.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-39">
								<td class="No-Table-Style TFN CellOverride-20" colspan="7">
									<p class="table-footnote ParaOverride-23">ACE <span class="table-footnote_symbol">=</span> angiotensin-&#173;converting enzyme; AIDS <span class="table-footnote_symbol">=</span> acquired immune deficiency syndrome; ANA <span class="table-footnote_symbol">=</span> antinuclear antibody; anti-&#173;dsDNA <span class="table-footnote_symbol">=</span> anti-&#173;double-&#173;stranded <br />DNA antibody; APMPPE <span class="table-footnote_symbol">=</span> acute posterior multifocal placoid pigment epitheliopathy; ARN = acute retinal necrosis; C3, C4 <span class="table-footnote_symbol">=</span> complement 3, complement 4; <br />c-&#173;ANCA <span class="table-footnote_symbol">=</span> c-&#173;anti-&#173;neutrophil cytoplasmic antibody; CMV <span class="table-footnote_symbol">=</span> cytomegalovirus; CNS <span class="table-footnote_symbol">=</span> central ner&#173;vous system; CSF <span class="table-footnote_symbol">=</span> cerebrospinal fluid; CT <span class="table-footnote_symbol">=</span> computed tomography; CXR <span class="table-footnote_symbol">=</span> chest x-&#173;ray; ELISA <span class="table-footnote_symbol">=</span> enzyme-&#173;linked immunosorbent assay; ESR <span class="table-footnote_symbol">=</span> erythrocyte sedimentation rate; FTA-&#173;ABS <span class="table-footnote_symbol">=</span> fluo&#173;rescent treponemal antibody absorption; GI <span class="table-footnote_symbol">=</span> gastrointestinal; GU <span class="table-footnote_symbol">=</span> genitourinary; HIV <span class="table-footnote_symbol">=</span> &#173;human immunodeficiency virus; IGRA <span class="table-footnote_symbol">=</span> interferon gamma release assay; IOL <span class="table-footnote_symbol">=</span> intraocular lens; IOP <span class="table-footnote_symbol">=</span> intraocular pressure; IV <span class="table-footnote_symbol">=</span> intravenous; JIA <span class="table-footnote_symbol">=</span> juvenile idiopathic arthritis; KP <span class="table-footnote_symbol">=</span> keratic precipitates; LP <span class="table-footnote_symbol">=</span> lumbar puncture; MEWDS <span class="table-footnote_symbol">=</span> multiple evanescent white dot syndrome; MHA-&#173;TP <span class="table-footnote_symbol">=</span> microhemagglutination assay–&#173;<span class="table-footnote_italic">Treponema pallidum;</span> MRI <span class="table-footnote_symbol">=</span> magnetic resonance imaging; PCR <span class="table-footnote_symbol">=</span> polymerase chain reaction; PIC <span class="table-footnote_symbol">=</span> punctate inner choroidopathy; PPD <span class="table-footnote_symbol">=</span> purified protein derivative; RF <span class="table-footnote_symbol">=</span> rheumatoid &#173;factor; RPR <span class="table-footnote_symbol">=</span> rapid plasma reagin; TB <span class="table-footnote_symbol">=</span> tuberculosis; VDRL = Venereal Disease Research Laboratory.</p>
								</td>
							</tr>
						</tbody>
					</table>
				</div>
				<div id="_idContainer011" class="Basic-Text-Frame">
					<p class="table-cont-line">(Continued)</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer014">
				<div id="_idContainer013" class="Basic-Text-Frame _idGenObjectStyleOverride-3">
					<p class="table-title"><span class="CharOverride-5">(continued)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer015" class="_idGenObjectStyleOverride-2">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer017">
				<div id="_idContainer016" class="Basic-Text-Frame">
					<p class="table-cont-line">(Continued)</p>
				</div>
			</div>
		</div>
		<div id="_idContainer018" class="Basic-Text-Frame _idGenObjectStyleOverride-3">
			<p class="table-title"><span class="CharOverride-5">(continued)</span></p>
		</div>
		<div id="_idContainer019" class="Basic-Text-Frame">
			<table id="table005" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-40" />
					<col class="_idGenTableRowColumn-41" />
					<col class="_idGenTableRowColumn-42" />
					<col class="_idGenTableRowColumn-41" />
					<col class="_idGenTableRowColumn-43" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-29">
						<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="5">
							<p class="table-title"><span class="table-number">Table 5-5</span> Diseases With Retinal Vasculitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Primarily Arteritis</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Primarily Phlebitis</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Arteritis and Phlebitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-23">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Systemic lupus erythematosus</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Sarcoidosis</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Toxoplasmosis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-21">
							<p class="table-body">Polyarteritis nodosa</p>
						</td>
						<td class="No-Table-Style CellOverride-21" />
						<td class="No-Table-Style CellOverride-21">
							<p class="table-body">Multiple sclerosis</p>
						</td>
						<td class="No-Table-Style CellOverride-21" />
						<td class="No-Table-Style CellOverride-21">
							<p class="table-body">Relapsing polychondritis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Syphilis</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Behçet disease</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Granulomatosis with polyangiitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-18">
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">HSV, VZV (ARN/BARN)</p>
							<p class="table-body">HSV, VZV (PORN)</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Birdshot chorioretinopathy</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Crohn disease</p>
							<p class="table-body">Frosted branch angiitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-8 _idGenCellOverride-3" rowspan="3">
							<p class="table-body">IRVAN</p>
							<p class="table-body ParaOverride-23">Churg-Strauss syndrome<br />Susac syndrome</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">HIV paraviral syndrome</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-body">Eales disease</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-44">
						<td class="No-Table-Style CellOverride-7" colspan="5">
							<p class="table-source-note">ARN = acute retinal necrosis; BARN = bilateral acute retinal necrosis; HIV = human immunodeficiency virus; HSV = herpes simplex virus; IRVAN = idiopathic retinal vasculitis, aneurysms, and neuroretinitis; PORN = progressive outer retinal necrosis; VZV = varicella-zoster virus.</p>
							<p class="table-source-note ParaOverride-24">Adapted with permission from Foster CS, Vitale AT. <span class="CharOverride-5">Diagnosis and Treatment of Uveitis.</span> 2nd ed. Jaypee Brothers Medical Publishers, New Delhi, India; 2012:123–128.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer020" class="Basic-Text-Frame">
			<table id="table006" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-45" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-46">
						<td class="No-Table-Style CellOverride-22">
							<p class="table-title"><span class="table-number">Table 5-6</span> Symptoms of Uveitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-47">
						<td class="No-Table-Style CellOverride-23">
							<p class="table-body ParaOverride-25">Redness</p>
							<p class="table-body ParaOverride-25">Pain</p>
							<p class="table-body ParaOverride-25">Photophobia</p>
							<p class="table-body ParaOverride-25">Epiphora</p>
							<p class="table-body ParaOverride-25">Visual disturbances</p>
							<p class="table-body ParaOverride-26">Diffuse blur, caused by</p>
							<p class="table-indent-1 ParaOverride-27">Refractive shift</p>
							<p class="table-indent-1 ParaOverride-27">Inflammatory cells</p>
							<p class="table-indent-1 ParaOverride-27">Cataract, calcific band keratopathy, macular edema, retinochoroiditis</p>
							<p class="table-body ParaOverride-28">Corneal, retinal, or optic disc edema</p>
							<p class="table-body ParaOverride-28">Floaters</p>
							<p class="table-body ParaOverride-28">Photopsias</p>
							<p class="table-body ParaOverride-28">Scotomata (central or peripheral)</p>
							<p class="table-body ParaOverride-28">Metamorphopsia</p>
							<p class="table-body ParaOverride-28">Nyctalopia</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer021" class="Basic-Text-Frame">
			<table id="table007" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-48" />
					<col class="_idGenTableRowColumn-49" />
					<col class="_idGenTableRowColumn-25" />
					<col class="_idGenTableRowColumn-50" />
					<col class="_idGenTableRowColumn-51" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-46">
						<td class="No-Table-Style CellOverride-22" colspan="5">
							<p class="table-title"><span class="table-number">Table 5-7</span> Signs of Uveitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-52">
						<td class="No-Table-Style CellOverride-23" />
						<td class="No-Table-Style CellOverride-23">
							<p class="table-body"><span class="CharOverride-6">Eyelid and skin</span></p>
							<p class="table-indent-1">Vitiligo</p>
							<p class="table-indent-1">Nodules </p>
							<p class="table-indent-1">Ptosis/lid edema</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Conjunctiva/sclera</span></p>
							<p class="table-indent-1">Perilimbal or diffuse injection </p>
							<p class="table-indent-1">Nodules</p>
							<p class="table-indent-1">Scleral thinning</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Corneal endothelium</span></p>
							<p class="table-indent-1">Keratic (cellular) precipitates (diffuse or gravitational)</p>
							<p class="table-indent-1">Fibrin</p>
							<p class="table-indent-1">Pigment (nonspecific)</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Anterior/posterior chamber</span></p>
							<p class="table-indent-1">Inflammatory cells</p>
							<p class="table-indent-1">Flare (proteinaceous influx)</p>
							<p class="table-indent-1">Pigment (nonspecific)</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Iris</span></p>
							<p class="table-indent-1">Nodules</p>
							<p class="table-indent-1">Posterior synechiae </p>
							<p class="table-indent-1">Atrophy</p>
							<p class="table-indent-1">Heterochromia</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Angle</span></p>
							<p class="table-indent-1">Peripheral anterior synechiae</p>
							<p class="table-indent-1">Nodules</p>
							<p class="table-indent-1">Vascularization</p>
						</td>
						<td class="No-Table-Style CellOverride-23" />
						<td class="No-Table-Style CellOverride-23">
							<p class="table-body"><span class="CharOverride-6">Intraocular pressure</span></p>
							<p class="table-indent-1">Hypotony</p>
							<p class="table-indent-1">High pressure</p>
							<p class="table-indent-1">Trabeculitis or secondary glaucoma</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Vitreous</span></p>
							<p class="table-indent-1">Inflammatory cells (single/clumped)</p>
							<p class="table-indent-1">Traction bands</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Pars plana</span></p>
							<p class="table-indent-1">Snowbanking</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Retina</span></p>
							<p class="table-indent-1">Inflammatory cells/thickening/whitening</p>
							<p class="table-indent-1">Inflammatory cuffing of blood vessels</p>
							<p class="table-indent-1">Neovascularization</p>
							<p class="table-indent-1">Edema</p>
							<p class="table-indent-1">Uveitic macular edema</p>
							<p class="table-indent-1">Epiretinal membranes</p>
							<p class="table-indent-1">Subretinal fluid</p>
							<p class="table-indent-1">Retinal pigment epithelium: <br />hypertrophy/clumping/loss</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Choroid</span></p>
							<p class="table-indent-1">Inflammatory infiltrate/thickening</p>
							<p class="table-indent-1">Atrophy</p>
							<p class="table-indent-1">Neovascularization</p>
							<p class="table-body ParaOverride-24"><span class="CharOverride-6">Optic nerve</span></p>
							<p class="table-indent-1">Edema (nonspecific)</p>
							<p class="table-indent-1">Neovascularization</p>
						</td>
						<td class="No-Table-Style CellOverride-23" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer024">
				<div id="_idContainer022" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.1.jpg" alt="" />
				</div>
				<div id="_idContainer023" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-1</span> Inflammatory cells in the anterior chamber (grade 4<span class="figure-caption_symbol">+</span>) of a patient with anterior uveitis. <span class="figure-source-note">(Courtesy of Emmett&#160;T. Cunningham Jr, MD, PhD, MPH.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer027">
				<div id="_idContainer025" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.2.jpg" alt="" />
				</div>
				<div id="_idContainer026" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-17"><span class="figure-number">Figure&#160;5-2</span> Aqueous flare (grade 4<span class="figure-caption_symbol">+</span>) in a <br />patient with acute anterior uveitis.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer030">
				<div id="_idContainer028" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.3.jpg" alt="" />
				</div>
				<div id="_idContainer029" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-3</span> Keratic precipitates (medium and small). <span class="figure-source-note">(Courtesy of Debra Goldstein, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer033">
				<div id="_idContainer031" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.4.jpg" alt="" />
				</div>
				<div id="_idContainer032" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-4</span> Large “mutton-&#173;fat” keratic precipitates in a patient with sarcoidosis. Large keratic precipitates such as &#173;these generally indicate a granulomatous disease pro&#173;cess. <span class="figure-source-note">(Courtesy of Debra Goldstein, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer036">
				<div id="_idContainer034" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-5</span> Mid-&#173;iris nodules (Busacca nodules) in 2 patients <span class="figure-caption_bold">(A, B)</span> with sarcoidosis. <span class="figure-source-note">(Part A cour</span><span class="figure-source-note">tesy of Debra Goldstein, MD. Part B courtesy of Wendy Smith, MD.)</span></p>
				</div>
				<div id="_idContainer035" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.5.png" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer039">
				<div id="_idContainer037" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.6.jpg" alt="" />
				</div>
				<div id="_idContainer038" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-6</span> Multiple posterior synechiae preventing complete dilation of the pupil. <span class="figure-source-note">(Courtesy of David Forster, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer040" class="Basic-Text-Frame">
			<table id="table008" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-41" />
					<col class="_idGenTableRowColumn-53" />
					<col class="_idGenTableRowColumn-54" />
					<col class="_idGenTableRowColumn-53" />
					<col class="_idGenTableRowColumn-55" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style TT" colspan="5">
							<p class="TT"><span class="table-number">&#173;Table&#160;5-8</span> Grading Scheme for Anterior Chamber Cells and Based on Standardization of Uveitis Nomenclature (SUN) Criteria</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Grade</p>
						</td>
						<td class="No-Table-Style TCH" />
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Number of Cells (High-&#173;Intensity <br />1 <span class="table-column-head_symbol">×</span> 1-mm Slit Beam)</p>
						</td>
						<td class="No-Table-Style TCH" />
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Flare</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-29">
						<td class="No-Table-Style TBF">
							<p class="table-body ParaOverride-23">0</p>
						</td>
						<td class="No-Table-Style TBF" />
						<td class="No-Table-Style TBF">
							<p class="table-body ParaOverride-29"><span class="table-body_symbol">&lt;</span>1</p>
						</td>
						<td class="No-Table-Style TBF" />
						<td class="No-Table-Style TBF">
							<p class="table-body">None</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-30">0.5<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">1–5</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Not applicable</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-23">1<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">6–15</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Faint</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-23">2<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">16–25</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Moderate (clear iris details)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-23">3<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">26–50</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Marked (hazy iris details)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-56">
						<td class="No-Table-Style TBL">
							<p class="table-body ParaOverride-23">4<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TBL" />
						<td class="No-Table-Style TBL">
							<p class="table-body ParaOverride-29"><span class="table-body_symbol">&gt;</span>50</p>
						</td>
						<td class="No-Table-Style TBL" />
						<td class="No-Table-Style TBL">
							<p class="table-body">Intense (fibrin or plasmoid aqueous)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-19">
						<td class="No-Table-Style TFN" colspan="5">
							<p class="table-source-note">Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of nomenclature for reporting clinical data. Results of the First International Workshop. <span class="table-footnote_italic">Am J Ophthalmol.</span> 2005;140(3):512.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer043">
				<div id="_idContainer041" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.7.jpg" alt="" />
				</div>
				<div id="_idContainer042" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-7</span> Grading scale for vitreous haze: representative standard images. Grade 4: Dense opacity obscuring optic nerve head. Grade 3: Optic nerve vis&#173;i&#173;ble, borders blurred, no ret&#173;i&#173;nal vessels seen. Grade 2: Significant blurring of optic nerve and ret&#173;i&#173;nal vessels but still vis&#173;i&#173;ble. Grade 1: Few opacities, mild blurring of optic nerve and ret&#173;i&#173;nal vessels. Trace (0.5+): Trace. Grade 0: Clear. <span class="figure-source-note">(Courtesy of NEI, originally published in Nussenblatt RB,&#160;Palestine AG,&#160;Chan CC, et&#160;al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.</span>&#160;<span class="figure-source-emphasis">Ophthalmology.</span> <span class="figure-source-note">1985;92(4):467–471.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer046">
				<div id="_idContainer044" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.8.jpg" alt="" />
				</div>
				<div id="_idContainer045" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-8</span> Slit-lamp technique for viewing anterior vitreous cells and opacity, demonstrated in a patient with amyloidosis. <span class="figure-source-note">(Courtesy of Emilio&#160;M. Dodds, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer047" class="Basic-Text-Frame">
			<table id="table009" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-41" />
					<col class="_idGenTableRowColumn-57" />
					<col class="_idGenTableRowColumn-58" />
					<col class="_idGenTableRowColumn-57" />
					<col class="_idGenTableRowColumn-59" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-29">
						<td class="No-Table-Style TT" colspan="5">
							<p class="TT"><span class="table-number">&#173;Table&#160;5-9</span> Grading Scheme for Vitreous Chamber Cells and Haze</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Grade</p>
						</td>
						<td class="No-Table-Style TCH" />
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Number of Cells in Retrolental Space <br />(High-&#173;Intensity 1<span class="table-column-head_symbol">×</span> 0.5-mm Slit Beam)</p>
						</td>
						<td class="No-Table-Style TCH" />
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Vitreous Haze</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-29">
						<td class="No-Table-Style TBF">
							<p class="table-body ParaOverride-23">0</p>
						</td>
						<td class="No-Table-Style TBF" />
						<td class="No-Table-Style TBF">
							<p class="table-body ParaOverride-29">0</p>
						</td>
						<td class="No-Table-Style TBF" />
						<td class="No-Table-Style TBF">
							<p class="table-body">Clear view of fundus</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-23">0.5<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">1–5</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Not applicable</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-23">1<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">6–10</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Faint</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-23">2<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">11–20</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Moderate (clear optic nerve details)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-23">3<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body ParaOverride-29">21–50</p>
						</td>
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB">
							<p class="table-body">Marked (hazy optic nerve details)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-56">
						<td class="No-Table-Style TBL">
							<p class="table-body ParaOverride-23">4<span class="table-body_symbol">+</span></p>
						</td>
						<td class="No-Table-Style TBL" />
						<td class="No-Table-Style TBL">
							<p class="table-body ParaOverride-29"><span class="table-body_symbol">&gt;</span>50</p>
						</td>
						<td class="No-Table-Style TBL" />
						<td class="No-Table-Style TBL">
							<p class="table-body">Intense (minimal/no optic nerve detail)</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer048" class="Basic-Text-Frame">
			<table id="table010" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-60" />
					<col class="_idGenTableRowColumn-61" />
					<col class="_idGenTableRowColumn-54" />
					<col class="_idGenTableRowColumn-61" />
					<col class="_idGenTableRowColumn-62" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-29">
						<td class="No-Table-Style TT" colspan="5">
							<p class="TT"><span class="table-number">&#173;Table&#160;5–10</span> Patient &#173;Factors in Diagnosis of Uveitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Patient Characteristics</p>
						</td>
						<td class="No-Table-Style TCH" />
						<td class="No-Table-Style TCH">
							<p class="table-column-head">&#173;Family and Social History</p>
						</td>
						<td class="No-Table-Style TCH" />
						<td class="No-Table-Style TCH">
							<p class="table-column-head">Additional Modifying &#173;Factors</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style TBF _idGenCellOverride-4" rowspan="3">
							<p class="table-body">Age</p>
							<p class="table-body">Sex</p>
							<p class="table-body">Race/ethnicity/country of origin</p>
						</td>
						<td class="No-Table-Style TBF" />
						<td class="No-Table-Style TBF">
							<p class="table-body">&#173;Family or personal history of autoimmune disease/endemic infection</p>
						</td>
						<td class="No-Table-Style TBF" />
						<td class="No-Table-Style TBF">
							<p class="table-body">Immunization history</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style TB CellOverride-15" />
						<td class="No-Table-Style TB CellOverride-15">
							<p class="table-body">Medi&#173;cation or intravenous drug use</p>
						</td>
						<td class="No-Table-Style TB CellOverride-15" />
						<td class="No-Table-Style TB CellOverride-15">
							<p class="table-body">Immune system status</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-30">
						<td class="No-Table-Style TB CellOverride-15" />
						<td class="No-Table-Style TB CellOverride-15" rowspan="5">
							<p class="table-body">Tobacco exposure</p>
							<p class="table-body">Occupation</p>
							<p class="table-body">Sexual practices</p>
							<p class="table-body">Eating habits</p>
							<p class="table-body">Pets and animal exposures</p>
						</td>
						<td class="No-Table-Style TB CellOverride-15" />
						<td class="No-Table-Style TB CellOverride-15 _idGenCellOverride-3" rowspan="6">
							<p class="table-body">Systemic medi&#173;cations</p>
							<p class="table-body">Trauma history</p>
							<p class="table-body">Travel history</p>
							<p class="table-body">Hospital admissions/surgery</p>
							<p class="table-body">Indwelling lines/instrumentation</p>
							<p class="table-body">Review of systems and existing medical conditions</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
						<td class="No-Table-Style TB" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-56">
						<td class="No-Table-Style TBL" />
						<td class="No-Table-Style TBL" />
						<td class="No-Table-Style TBL" />
						<td class="No-Table-Style TBL" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer049" class="Basic-Text-Frame">
			</div>
		</div>
		<div id="_idContainer050" class="Basic-Text-Frame">
			<table id="table011" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-63" />
					<col class="_idGenTableRowColumn-64" />
					<col class="_idGenTableRowColumn-65" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-29">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 5-11</span> Laboratory  Tests and Imaging Studies Used in Uveitis Evaluations</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-24">
							<p class="table-column-head">Test</p>
						</td>
						<td class="Basic-Table CellOverride-24" />
						<td class="Basic-Table CellOverride-24">
							<p class="table-column-head">Indications and/or Potential Diagnoses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-25">
							<p class="table-head">Hematologic blood tests</p>
						</td>
						<td class="Basic-Table CellOverride-25" />
						<td class="Basic-Table CellOverride-25" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-26">
							<p class="table-body">Complete blood count with differential</p>
						</td>
						<td class="Basic-Table CellOverride-26" />
						<td class="Basic-Table CellOverride-26">
							<p class="table-body">IMT and select antibiotics/antivirals, leukemia, lymphoma, immune status (eg., neutropenia)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Erythrocyte sedimentation rate</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Giant cell arteritis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Interferon-gamma release assay</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Latent and active tuberculosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">T-cell subsets</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Opportunistic infection, HIV</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-28">
							<p class="table-head">Serologic tests</p>
						</td>
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Liver function tests (ALT, AST)</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">IMT (antimetabolites),  sarcoidosis, hepatitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Serum urea nitrogen, creatinine</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">IMT (T-cell inhibitors), glomerulonephritis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Angiotensin-converting enzyme, lysozyme, calcium</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Sarcoidosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Antinuclear antibody</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Connective tissue disease, juvenile idiopathic arthritis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Antiphospholipid&#160;antibodies</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Vascular occlusion</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Rheumatoid factor, anticitrullinated <br />protein antibody</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Rheumatoid arthritis, juvenile idiopathic arthritis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">HLA testing</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-indent-1">HLA-B27</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Spondyloarthropathy; acute anterior uveitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-indent-1">HLA-A29</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Birdshot chorioretinopathy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-indent-1">HLA-B51 (rarely obtained and of limited value)</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Behçet disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table CellOverride-27">
							<p class="table-indent-1">HLA DR, DQ class II</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">TINU syndrome</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">ANCA testing—c-ANCA (proteinase 3) and p-ANCA (myeloperoxidase)</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Systemic vasculitides</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-32">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">VDRL/RPR (nontreponemal tests); syphilis IgG/FTA-ABS/MHA-TP (treponomal-&#173;specific tests)</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Syphilis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-29">
							<p class="table-body">Lyme disease serology</p>
						</td>
						<td class="Basic-Table CellOverride-29" />
						<td class="Basic-Table CellOverride-29">
							<p class="table-body">Lyme disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-30">
							<p class="table-body"><span class="CharOverride-5">Brucella</span> species serology</p>
						</td>
						<td class="Basic-Table CellOverride-30" />
						<td class="Basic-Table CellOverride-30">
							<p class="table-body">Brucellosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-31">
							<p class="table-body"><span class="CharOverride-5">Toxoplasma gondii</span> serology</p>
						</td>
						<td class="Basic-Table CellOverride-31" />
						<td class="Basic-Table CellOverride-31">
							<p class="table-body">Toxoplasmosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-32">
							<p class="table-body">Fungal serology (complement fixation)</p>
						</td>
						<td class="Basic-Table CellOverride-32" />
						<td class="Basic-Table CellOverride-32">
							<p class="table-body">Coccidioidomycosis, typically not obtained for presumed ocular histoplasmosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-26">
							<p class="table-body"><span class="italic-table">Bartonella quintana</span> and <span class="italic-table">B henselae</span> serology</p>
						</td>
						<td class="Basic-Table CellOverride-26" />
						<td class="Basic-Table CellOverride-26">
							<p class="table-body">Cat-scratch disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">EBV, HSV, VZV, CMV serology</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Viral uveitis (little benefit unless negative)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">HIV serology/Western blot</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">HIV/AIDS, opportunistic infections, vascular occlusions</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-28">
							<p class="table-head">Cerebrospinal fluid (CSF) studies</p>
						</td>
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-32">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Protein, glucose, cell counts/cytology, cultures, Gram stain, CSF VDRL, oligoclonal bands</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">APMPPE, VKH syndrome, syphilis and other infection, malignancy, primary intraocular lymphoma, MS</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-29">
						<td class="Basic-Table CellOverride-33">
							<p class="table-head">Urine studies</p>
						</td>
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-head"><span class="CharOverride-7">Urinalysis for hematuria, proteinuria, and casts; urinary beta-2</span><span class="xref-table CharOverride-8"> microglobulin</span></p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">IMT (cyclophosphamide toxicity), ANCA-associated vasculities; <span class="xref-table CharOverride-9">TINU syndrome</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-28">
							<p class="table-head">Radiographic studies</p>
						</td>
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Chest radiograph</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Tuberculosis, sarcoidosis, granulomatosis with polyangiitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table TBL CellOverride-34">
							<p class="table-body">Sacroiliac joint x-rays</p>
						</td>
						<td class="Basic-Table TBL CellOverride-34" />
						<td class="Basic-Table TBL CellOverride-34">
							<p class="table-body">HLA-B27–associated ankylosing spondylitis</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer051" class="Basic-Text-Frame">
			<table id="table012" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-63" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-66" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table TCH">
							<p class="table-column-head">Test</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Indications and/or Potential Diagnoses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TBF">
							<p class="table-body">CT of chest</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">Tuberculosis, sarcoidosis, granulomatosis with polyangiitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-35">
							<p class="table-body">CT/magnetic resonance imaging of brain and orbits</p>
						</td>
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35">
							<p class="table-body">Sarcoidosis, central nervous system lymphoma, toxoplasmosis, MS</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-29">
							<p class="table-head">Intraocular fluid analysis and tissue biopsy</p>
						</td>
						<td class="Basic-Table CellOverride-29" />
						<td class="Basic-Table CellOverride-29" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Intraocular fluid analysis for local antibody production (limited availability)</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">HSV, VZV, CMV, rubella virus, <span class="italic-table">Toxoplasma </span>organisms</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-67">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Polymerase chain reaction</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-indent-1 ParaOverride-31">Viridae: HS1, HS2, VZV, CMV, EBV, Ebola, Zika, West Nile, rubella</p>
							<p class="table-indent-1 ParaOverride-31">Bacteria: universal 16S subunit for pan-bacteria; individual PCR primers available for many individual bacteria, varies by laboratory</p>
							<p class="table-indent-1 ParaOverride-31">Protozoa: <span class="italic-table">Toxoplasma gondii, Onchocerca volvulus</span></p>
							<p class="table-indent-1 ParaOverride-31">Fungi: universal 18S or 28S subunit for panfungi: <span class="italic-table">Candida albicans, Aspergillus </span>species (28S&#160;rRNA gene)</p>
							<p class="table-indent-1 ParaOverride-31">Intraocular lymphoma (IgH, TCR, <span class="italic-table">MYD88</span>, others)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Endoretinal, subretinal, choroidal biopsy</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Necrotizing retinitis, neoplasia (central nervous system lymphoma)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Skin, conjunctival, lacrimal biopsy</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Sarcoidosis, infection, lymphoma, amyloidosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-32">
						<td class="Basic-Table CellOverride-38">
							<p class="table-head">Stool for detection pathogenic of microorganisms</p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body ParaOverride-23">Parasitic diseases; viruses, bacteria, fungi</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-68">
						<td class="Basic-Table CellOverride-39" colspan="3">
							<p class="table-body ParaOverride-23">ALT = alanine aminotransferase; ANCA = antineutrophil cytoplasmic antibody; <br />APMPPE = acute posterior multifocal placoid pigment epitheliopathy; AST = aspartate aminotransferase; c-ANCA = cytoplasmic ANCA; CMV = cytomegalovirus; CSF = cerebrospinal fluid; CT = computed tomography; EBV = Epstein-&#173;Barr virus; FTA-ABS&#160;= fluorescent treponemal antibody absorption; HIV = human immunodeficiency virus; HLA = human leukocyte antigen; <br />HSV = herpes simplex virus; IgH = immunoglobulin heavy locus; IMT = immunomodulatory therapy; MHA-TP&#160;= microhemagglutination assay–<span class="italic-table">Treponema pallidum;</span> MS = multiple sclerosis; p-ANCA = perinuclear ANCA; RPR = rapid plasma reagin; TCR = T-cell receptor; TINU = tubulointerstitial nephritis and uveitis syndrome; VDRL = Venereal Disease Research Laboratory; VKH&#160;= Vogt-Koyanagi-Harada; VZV = varicella-zoster virus.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer054">
				<div id="_idContainer052" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.9.jpg" alt="" />
				</div>
				<div id="_idContainer053" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-9</span> Optical coherence tomography image of uveitic macular edema in a patient with juvenile idiopathic arthritis–&#173;associated uveitis. <span class="figure-source-note">(Courtesy of Thellea&#160;K. Leveque, MD, MPH.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer057">
				<div id="_idContainer055" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.10.png" alt="" />
				</div>
				<div id="_idContainer056" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-10</span> Enhanced-depth imaging optical coherence tomography in a patient with Vogt-&#173;Koyanagi-&#173;Harada syndrome <span class="figure-caption_bold">A,</span> During quiescence with relatively normal choroidal thickness <span class="figure-caption-italic">(arrows)</span>. <span class="figure-caption_bold">B,</span> During uveitis activity with diffuse choroidal thickening <span class="figure-caption-italic">(arrows)</span>. <span class="figure-caption_italic CharOverride-10">(Courtesy Thellea&#160;K. Leveque, MD, MPH.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer060">
				<div id="_idContainer058" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C05_p067_092_8P-web-resources/image/Fig5.11.jpg" alt="" />
				</div>
				<div id="_idContainer059" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;5-11</span> Late transit phase fluorescein angiogram of the left eye of a patient with sarcoid-&#173;associated anterior uveitis showing a petalloid pattern typical of uveitic macular edema. <span class="figure-caption_italic CharOverride-10">(Courtesy of Ramana&#160;S. Moorthy, MD.)</span></p>
				</div>
			</div>
		</div>
	</body>
</html>
